260 related articles for article (PubMed ID: 38313430)
1. Surprising magic of CD24 beyond cancer.
Wang H; Shi P; Shi X; Lv Y; Xie H; Zhao H
Front Immunol; 2023; 14():1334922. PubMed ID: 38313430
[TBL] [Abstract][Full Text] [Related]
2. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
Moon SY; Han M; Ryu G; Shin SA; Lee JH; Lee CS
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894750
[TBL] [Abstract][Full Text] [Related]
3. CD24: from A to Z.
Fang X; Zheng P; Tang J; Liu Y
Cell Mol Immunol; 2010 Mar; 7(2):100-3. PubMed ID: 20154703
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD24 as a novel immunotherapy for solid cancers.
Yang Y; Zhu G; Yang L; Yang Y
Cell Commun Signal; 2023 Nov; 21(1):312. PubMed ID: 37919766
[TBL] [Abstract][Full Text] [Related]
6. CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y; Harutani Y; Oyanagi J; Akamatsu H; Murakami E; Shibaki R; Hayata A; Sugimoto T; Tanaka M; Takakura T; Furuta K; Okuda Y; Sato K; Teraoka S; Ueda H; Tokudome N; Kitamura Y; Fukuoka J; Nakanishi M; Koh Y; Yamamoto N
Cancer Sci; 2021 Jan; 112(1):72-80. PubMed ID: 33084148
[TBL] [Abstract][Full Text] [Related]
7. Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.
Wu H; Liu J; Wang Z; Yuan W; Chen L
CNS Neurosci Ther; 2021 Oct; 27(10):1105-1117. PubMed ID: 34363319
[TBL] [Abstract][Full Text] [Related]
8. CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma.
Wu X; Srinivasan P; Basu M; Zimmerman T; Li S; Wang Y; Zheng P; Liu Y; Sandler AD
Front Immunol; 2023; 14():1176370. PubMed ID: 37346042
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.
Wei HJ; Yin T; Zhu Z; Shi PF; Tian Y; Wang CY
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):428-34. PubMed ID: 21813394
[TBL] [Abstract][Full Text] [Related]
10. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
11. CD24-Siglec interactions in inflammatory diseases.
Liu Y; Zheng P
Front Immunol; 2023; 14():1174789. PubMed ID: 37228622
[TBL] [Abstract][Full Text] [Related]
12. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract][Full Text] [Related]
13. The CD24 surface antigen in neural development and disease.
Gilliam DT; Menon V; Bretz NP; Pruszak J
Neurobiol Dis; 2017 Mar; 99():133-144. PubMed ID: 27993646
[TBL] [Abstract][Full Text] [Related]
14. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
[TBL] [Abstract][Full Text] [Related]
15. CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
Geng R; Harland N; Montes-Mojarro IA; Fend F; Aicher WK; Stenzl A; Amend B
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628262
[TBL] [Abstract][Full Text] [Related]
16. CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.
Higashi M; Momose S; Takayanagi N; Tanaka Y; Anan T; Yamashita T; Kikuchi J; Tokuhira M; Kizaki M; Tamaru JI
J Pathol Clin Res; 2022 Jul; 8(4):340-354. PubMed ID: 35289116
[TBL] [Abstract][Full Text] [Related]
17. Twist2 and CD24 expression alters renal microenvironment in obesity associated kidney cancer.
Yang XF; Ma G; Feng NH; Yu DS; Wu Y; Li C
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):358-364. PubMed ID: 29424894
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
19. CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy.
Ni YH; Zhao X; Wang W
Curr Gene Ther; 2020; 20(2):109-126. PubMed ID: 32576128
[TBL] [Abstract][Full Text] [Related]
20. Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
Chan SH; Tsai KW; Chiu SY; Kuo WH; Chen HY; Jiang SS; Chang KJ; Hung WC; Wang LH
Mol Cancer Ther; 2019 Jan; 18(1):147-161. PubMed ID: 30381446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
